Table 1 Cardiovascular adverse events following CAR T-cell therapy

Burstein, et al. 2018²⁴

Pediatric B-ALL

98

Ad Hoc

9 (9.2%)

N/A

N/A

N/A

N/A

Alvi, et al. 2019²⁵

DLBCL & MM

137

Ad Hoc

6 (4.4%)

5 (3.6%)

N/A

6 (4.4%)

N/A

Lefebvre, et al. 2020²⁶

NHL, B-ALL, & CLL

145

ACC/AHA MACE

22 (15.2%)

11 (7.6%)

2 (1.4%)

2 (1.4%)

N/A

Shalabi, et al. 2020²⁷

Pediatric B-ALL & NHL

52

Ad Hoc

6 (11.5%)

N/A

N/A

N/A

N/A

Ganatra, et al. 2020²⁸

NHL

187

Ad Hoc

19 (10.2%)

13 (7.0%)

N/A

N/A

N/A

Brammer, et al. 2021²⁹

NHL

90

CTCAE

1 (1.1%)

11 (12.2%)

N/A

N/A

Myocarditis: 2 (2.2%)

Wudhikarn, et al. 2020³¹

DLBCL

60

CTCAE

3 (5.0%)

8 (13.3%)

N/A

N/A

Pericardial Effusion: 1 (1.7%)

Qi, et al. 2021³⁰

B-ALL, NHL, & MM

126

CTCAE

16 (12.7%)

8 (6.3%)

10 (7.9%)

N/A

N/A

Steiner, et al. 2022³⁵

DLBCL

165

ACC/AHA MACE

4 (2.4%)

21 (12.7%)

3 (1.8%)

1 (0.6%)

CVA: 4 (2.4%)

Lee, et al. 2023³²

MM

78

ESC/ICOS

4 (5.1%)

11 (14.1%)

N/A

1 (1.3%)

N/A

Lee, et al. 2023³³

NHL

90

ESC/ICOS

1 (1.1%)

10 (11.1%)

N/A

N/A

Myocarditis: 1 (1.1%)

Mahmood, et al. 2023³⁴

NHL & B-ALL

202

Ad Hoc

26 (12.9%)

N/A

11 (5.4%)

1 (0.5%)

N/A

Patel, et al. 2024²³

NHL, CLL, & MM

75

Ad Hoc

3 (4.0%)

6 (8.0%)

N/A

1 (1.3%)

N/A

Lefebvre, et al. 2023⁴⁰ (Prospective)

NHL & B-ALL

44

ACC/AHA MACE

1 (2.3%)

1 (2.3%)

N/A

N/A

N/A

Korell, et al. 2023⁴¹ (Prospective)

NHL, B-ALL, & MM

137

ACC/AHA MACE

17 (12.4%)

N/A

N/A

N/A

N/A